LSD
lysergic acid diethylamide
6Node page
what any key link opens
psx:substance/lsd/src/doi:10.1097/hrp.0000000000000439
src2026-10-03recordconsumed
psx:substance/lsd/src/doi:10.1097/hrp.0000000000000439
no derivations recorded for this key
← back to the archive1Provenance card
the boundary, as counts
3331 with DOI
26 strong · 6 moderate · 1 weak
0no compilation run
16 other runs
75last ruled 2026-10-03
32 awaiting a ruling
102026-10-19T20:32:32.507Z
notice · info card · emergency
00 with no results
queries and counts on the build
10274 supported
74 supported · 28 not
0received
consent field ships in Phase 4
341
derivations recorded for this entity
2Build
one panel per compilation run
Other runs
- findings run2026-08-19failed15 min102 entriesrun/1c0ee90a…
- findings run2026-08-19failed15 minrun/9bfe8fae…
- findings run2026-08-19failed45 minrun/6b59a6a5…
- findings run2026-08-20completed29 minrun/bd5dfd79…
- brief run2026-09-18failed15 minrun/17d1cf3a…
- brief run2026-09-18failed23 minrun/174d8129…
- brief run2026-09-18completed15 minrun/277733d4…
- brief run2026-09-22completed4 minrun/3ab2c8cc…
- brief run2026-09-22completed5 minrun/cf82bfe4…
- brief run2026-09-23completed2 minrun/af0dca76…
- brief run2026-09-27completed3 minrun/74090ed1…
- brief run2026-09-27completed3 minrun/69f96ff8…
- brief run2026-09-27completed6 minrun/9c00cf4b…
- brief run2026-09-27completed4 minrun/2805f59c…
- brief run2026-09-27completed4 minrun/507aef3b…
- brief run2026-09-28completed3 minrun/a03fe9e2…
3Sources
32 consumed · sorted by year · feeds = sections resting on it
| year | source | tier | status | feeds |
|---|---|---|---|---|
| 2026 | LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trialDaldegan-Bueno D, Donegan CJ, Sumner R, Forsyth A, et al., Muthukumaraswamy S · Progress in Neuro-Psychopharmacology and Biological Psychiatrydoi:10.1016/j.pnpbp.2026.111645 | moderate | consumed | 1 section |
| 2025 | Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover StudyArikci D, Holze F, Mueller L, Vizeli P, Rudin D, Luethi D, Hysek CM, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3726 | strong | consumed | 2 sections |
| 2025 | Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I TrialBecker AM, Humbert-Droz M, Mueller L, Jelušić A, Tolev A, Straumann I, Avedisian I, Erne L, Thomann J, Luethi D, Grünblatt E, Meyer Zu Schwabedissen H, Liechti ME · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.3618 | strong | consumed | 3 sections |
| 2025 | Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic ReviewNeven A, Blom JD · Harvard Review of Psychiatrydoi:10.1097/hrp.0000000000000439 | strong | consumed | cited only |
| 2025 | Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studiesSabé M, Sulstarova A, Glangetas A, De Pieri M, et al., Kirschner M · Molecular Psychiatrydoi:10.1038/s41380-024-02800-5 | strong | consumed | 1 section |
| 2024 | Chemistry/structural biology of psychedelic drugs and their receptor(s)Gumpper RH, Nichols DE · British Journal of Pharmacologydoi:10.1111/bph.17361 | strong | consumed | 2 sections |
| 2024 | LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-upHolze F, Gasser P, Müller F, Strebel M, Liechti ME · British Journal of Psychiatrydoi:10.1192/bjp.2024.99 | moderate | consumed | 1 section |
| 2024 | Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxinsRouaud A, Calder AE, Hasler G · Journal of Psychopharmacologydoi:10.1177/02698811231225609 | strong | consumed | 1 section |
| 2024 | New-Onset Seizures in an Adolescent Following Use of LSD while on Low-Dose Lithium Therapy: A Case StudyEdwards C, Van Gerpen S, Anand V · South Dakota Medicinepmid:38986146 | moderate | consumed | 1 section |
| 2024 | Pharmacological and non-pharmacological predictors of the LSD experience in healthy participantsVizeli P, Studerus E, Holze F, Schmid Y, Dolder PC, Ley L, Straumann I, Becker AM, Müller F, Arikci D, Liechti ME · Translational Psychiatrydoi:10.1038/s41398-024-03074-9 | strong | consumed | 1 section |
| 2023 | Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participantsLey L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-023-01607-2 | strong | consumed | 5 sections |
| 2023 | Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyHolze F, Gasser P, Müller F, Dolder PC, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2022.08.025 | strong | consumed | 1 section |
| 2023 | Psychedelics promote plasticity by directly binding to BDNF receptor TrkBMoliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, Antenucci L, Kot EF, Goncharuk SA, Kaurinkoski K, Kuutti M, Fred SM, Elsilä LV, Sakson S, Cannarozzo C, Diniz CRAF, Seiffert N, Rubiolo A, Haapaniemi H, Meshi E, Nagaeva E, Öhman T, Róg T, Kankuri E, Vilar M, Varjosalo M, Korpi ER, Permi P, Mineev KS, Saarma M, Vattulainen I, Casarotto PC, Castrén E · Nature Neurosciencedoi:10.1038/s41593-023-01316-5 | strong | consumed | 3 sections |
| 2022 | Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjectsHolze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, Kuehne SS, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-022-01297-2 | strong | consumed | 2 sections |
| 2022 | Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participantsMüller F, Kraus E, Holze F, Becker A, Ley L, Schmid Y, Vizeli P, Liechti ME, Borgwardt S · Psychopharmacologydoi:10.1007/s00213-022-06066-z | strong | consumed | 1 section |
| 2022 | Safety pharmacology of acute LSD administration in healthy subjectsHolze F, Caluori TV, Vizeli P, Liechti ME · Psychopharmacologydoi:10.1007/s00213-021-05978-6 | strong | consumed | 1 section |
| 2021 | A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteersRamaekers JG, Hutten N, Mason NL, Dolder P, Theunissen EL, Holze F, Liechti ME, Feilding A, Kuypers KP · Journal of Psychopharmacologydoi:10.1177/0269881120940937 | strong | consumed | cited only |
| 2021 | Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjectsHolze F, Vizeli P, Müller F, Ley L, Duerig R, Varghese N, Zizzari P, Liechti ME · Neuropsychopharmacologydoi:10.1038/s41386-020-00883-6 | strong | consumed | 3 sections |
| 2021 | Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reportsJohnson MW, et al.url:2d4d277ba0208a82 | weak | consumed | cited only |
| 2021 | Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysisVizeli P, Straumann I, Holze F, Schmid Y, Dolder PC, Liechti ME · Scientific Reportsdoi:10.1038/s41598-021-90343-y | strong | consumed | 2 sections |
| 2021 | Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy ParticipantsHolze F, Liechti ME, Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Duthaler U, Feilding A, Ramaekers JG, Kuypers KPC · Clinical Pharmacology and Therapeuticsdoi:10.1002/cpt.2057 | strong | consumed | 2 sections |
| 2020 | Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin ReceptorKim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL · Celldoi:10.1016/j.cell.2020.08.024 | strong | consumed | 3 sections |
| 2018 | A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPDHalpern JH, Lerner AG, Passie T · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2016_457 | moderate | consumed | 1 section |
| 2018 | Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic PerspectivesMartinotti G, Santacroce R, Pettorruso M, Montemitro C, Spano MC, Lorusso M, Di Giannantonio M, Gallimberti L · Brain Sciencesdoi:10.3390/brainsci8030047 | moderate | consumed | 1 section |
| 2018 | Psychedelics Promote Structural and Functional Neural PlasticityLy C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, Burbach KF, Soltanzadeh Zarandi S, Sood A, Paddy MR, Duim WC, Dennis MY, McAllister AK, Ori-McKenney KM, Gray JA, Olson DE · Cell Reportsdoi:10.1016/j.celrep.2018.05.022 | strong | consumed | 2 sections |
| 2017 | Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsDolder PC, Schmid Y, Steuer AE, Kraemer T, Rentsch KM, Hammann F, Liechti ME · Clinical Pharmacokineticsdoi:10.1007/s40262-017-0513-9 | strong | consumed | 2 sections |
| 2016 | Increased Global Functional Connectivity Correlates with LSD-Induced Ego DissolutionTagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R · Current Biologydoi:10.1016/j.cub.2016.02.010 | strong | consumed | 2 sections |
| 2016 | Neural correlates of the LSD experience revealed by multimodal neuroimagingCarhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ · Proceedings of the National Academy of Sciencesdoi:10.1073/pnas.1518377113 | strong | consumed | 1 section |
| 2016 | PsychedelicsNichols DE · Pharmacological Reviewsdoi:10.1124/pr.115.011478 | strong | consumed | 7 sections |
| 2015 | Acute Effects of Lysergic Acid Diethylamide in Healthy SubjectsSchmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME · Biological Psychiatrydoi:10.1016/j.biopsych.2014.11.015 | strong | consumed | 2 sections |
Show all 33 sources — 3 more
| year | source | tier | status | feeds |
|---|---|---|---|---|
| 2014 | The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsCarhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D · Frontiers in Human Neurosciencedoi:10.3389/fnhum.2014.00020 | strong | consumed | 1 section |
| 2012 | Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trialsKrebs TS, Johansen PØ · Journal of Psychopharmacologydoi:10.1177/0269881112439253 | strong | consumed | cited only |
| — | Crystal Structure of an LSD-Bound Human Serotonin Receptordoi:10.1016/j.cell.2016.12.033 | — | unknown | cited only |
4Docket
one filing per activity — decisions, correspondence, reports
awaiting ruling — 32
- safety_finding · oral · toxicity · safety_margincited2026-08-20
- safety_finding · toxicity · mortality_record2026-08-20
- safety_finding · toxicity · adulterant_hazard2026-08-20
- safety_finding · toxicity · acute_toxicitycited2026-08-20
- safety_finding · toxicity · cardiovascularcited2026-08-20
- safety_finding · toxicity · cardiovascularcited2026-08-20
- safety_finding · toxicity · receptor_concern2026-08-20
- safety_finding · toxicity · cardiovascular2026-08-20
- safety_finding · toxicity · study_safetycited2026-08-20
- safety_finding · toxicity · study_safetycited2026-08-20
- safety_finding · psychological_risks · hppd2026-08-20
- safety_finding · psychological_risks · hppd2026-08-20
- safety_finding · psychological_risks · hppd2026-08-20
- safety_finding · psychological_risks · hppdcited2026-08-20
- safety_finding · psychological_risks · hppd2026-08-20
- safety_finding · psychological_risks · psychosiscited2026-08-20
- safety_finding · psychological_risks · psychosiscited2026-08-20
- safety_finding · psychological_risks · psychosis2026-08-20
- safety_finding · toxicity · serotonergic2026-08-20
- safety_finding · toxicity · serotonergic2026-08-20
- safety_finding · toxicity · neurological2026-08-20
- safety_finding · toxicity · neurologicalcited2026-08-20
- safety_finding · toxicity · neurologicalcited2026-08-20
- safety_finding · toxicity · neurologicalcited2026-08-20
- safety_finding · toxicity · serotonergic2026-08-20
- safety_finding · oral · toxicity · serotonergiccited2026-08-20
- safety_finding · oral · toxicity · study_safetycited2026-08-20
- safety_finding · toxicity · serotonergic2026-08-20
- safety_finding · toxicity · serotonergic2026-08-20
- safety_finding · toxicity · reproductive2026-08-20
- safety_finding · toxicity · neurological2026-08-20
- safety_finding · toxicity · cardiovascular2026-08-20
0012026-04-19revisionRevision 1
Initial LLM generation (v5 pipeline, wiki)
psx:substance/lsd/version/10022026-06-04proposal30 value proposals approved together
one review action inferred from a shared reviewer and instant — the graph records one activity per proposal
psx:substance/lsd/proposal/dose_tier/d6efb877-0f42-4a97-9d6f-87b5494be76730 items in this filing
- dose_tier · light
- dose_tier · common
- dose_tier · strong
- dose_tier · heavy
- timeline · oral · onset
- timeline · oral · come_up
- timeline · oral · ascent
- timeline · oral · peak
- timeline · oral · plateau
- timeline · oral · resolution
- timeline · oral · afterglow
- toxicity
- dependence · full
- withdrawal
- tolerance
- dosage · oral
- duration · oral · onset
- duration · oral · come_up
- duration · oral · peak
- duration · oral · offset
- duration · oral · total
- duration · oral · aftereffects
- contraindication · psychiatric
- contraindication · psychiatric
- contraindication · neurological
- contraindication · other
- contraindication · cardiovascular
- contraindication · pregnancy_breastfeeding
- contraindication · other
0032026-06-04publicationPublication — backfill
0042026-08-24revisionr1.a1
technical error
psx:substance/lsd/version/20052026-09-20revisionr1.a2
no edit summary recorded
psx:substance/lsd/version/30062026-09-20publicationPublication — publishagent-psx (local dev)
0072026-09-22revisionr1.a3
no edit summary recorded
psx:substance/lsd/version/40082026-09-23publicationPublication — publishChris
0092026-09-23revisionr1.a4
no edit summary recorded
psx:substance/lsd/version/50102026-09-24publicationPublication — publishagent-psx (local dev)
0112026-09-27revisionr1.a5
brief-overview retired 2026-09-30 (founder): Description reads the essential summary for every substance.
psx:substance/lsd/version/60122026-10-03revisionr1.a6
Restore reagent testing, appearance and the identification guide carried by r1. They were dropped when amendment r1.a2 was created on 2026-09-20: the amendment copier carried only the summary columns (fixed 7d6e6ade8). Values copied unchanged from r1.
psx:substance/lsd/version/70132026-10-03publicationPublication — publishagent-psx
0142026-10-03revisionr1.a7
no edit summary recorded
psx:substance/lsd/version/8
5Issued documents
what the notice, info card and emergency page said, by hash
| document | content hash | issued | from version | superseded |
|---|---|---|---|---|
| emergency | c15c760aabf6f0fcf5b6fc6b… | 2026-10-19 20:32 | Revision 7 | current |
| info_card | a8d971188c3ca510a5c975fe… | 2026-10-19 20:32 | Revision 7 | current |
| info_card | 4c6647f545c338ee3cbb4a63… | 2026-10-03 21:31 | Revision 7 | superseded2026-10-19 |
| info_card | 5663c86ee3b8f14c6bfbe8f8… | 2026-09-24 10:06 | Revision 5 | superseded2026-10-03 |
| info_card | 2a2db6475e85b8efd25000be… | 2026-09-23 07:47 | Revision 4 | superseded2026-09-24 |
| notice | f069a9dea47b308467344618… | 2026-09-23 07:47 | Revision 4 | current |
| info_card | ab88b29eebc8cacc6ecfe7af… | 2026-09-20 08:15 | Revision 3 | superseded2026-09-23 |
| emergency | 3f0909c25c714d225b4bb3e3… | 2026-09-04 04:30 | Revision 1 | superseded2026-10-19 |
| info_card | 661b6d0eb350b1e2bb2cc63c… | 2026-09-04 04:30 | Revision 1 | superseded2026-09-20 |
| notice | 64878b43a1d2932a5305f55b… | 2026-09-04 04:30 | Revision 1 | superseded2026-09-23 |